Amyloid Against Amyloid: Dimeric Amyloid Fragment Ameliorates Cognitive Impairments by Direct Clearance of Oligomers and Plaques

Authors
Lee, HeeYangBaek, SeungyeopCha, MinhaeYang, Seung-HoonCho, IllhwanShin, HeewonLee, SejinKim, Hye YunLee, SongminShin, JisuLee, DongheeKim, KyeonghwanPark, InWookYoon, SoljeeKIM, JI YOONPark, SeongJeongKim, Seong MukKim, Ko EunKim, Hye JuOh, Min-SeokLee, Gwan-HoYu, Byung-YongKannan, PriyadharshiniPark, Keun wanKim, YoungSoo
Issue Date
2023-02
Publisher
John Wiley & Sons Ltd.
Citation
Angewandte Chemie International Edition, v.62, no.7
Abstract
Amyloid-beta (A beta) in the form of neurotoxic aggregates is regarded as the main pathological initiator and key therapeutic target of Alzheimer's disease. However, anti-A beta drug development has been impeded by the lack of a target needed for structure-based drug design and low permeability of the blood-brain barrier (BBB). An attractive therapeutic strategy is the development of amyloid-based anti-A beta peptidomimetics that exploit the self-assembling nature of A beta and penetrate the BBB. Herein, we designed a dimeric peptide drug candidate based on the N-terminal fragment of A beta, DAB, found to cross the BBB and solubilize A beta oligomers and fibrils. Administration of DAB reduced amyloid burden in 5XFAD mice, and downregulated neuroinflammation and prevented memory impairment in the Y-maze test. Peptide mapping assays and molecular docking studies were utilized to elucidate DAB-A beta interaction. To further understand the active regions of DAB, we assessed the dissociative activity of DAB with sequence modifications.
Keywords
BLOOD-BRAIN-BARRIER; AGGREGATION; INHIBITORS; DISEASE; RAGE; Alzheimer' s Disease (AD); Amyloid-beta (A beta); Peptide Drug
ISSN
1433-7851
URI
https://pubs.kist.re.kr/handle/201004/75836
DOI
10.1002/anie.202210209
Appears in Collections:
KIST Article > 2023
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE